Nurse assistant with autism pens cease-and-desist to RFK Jr. over recent proposals
Days ago, the department contradicted that announcement describing different plans to study cases of autism. One certified nursing assistant told News 8 he feels any mass collection of confidential records has the potential to violate disability and privacy acts.
Ethan Payne is a certified nursing assistant who also has autism. He said when he heard nearly $50 million was set to be invested by the Department of Health and Human Services for collecting data to study cases of autism, he immediately was concerned about how it would uphold the Americans with Disabilities Act, as well as HIPPA, and the potential of discriminatory practices.
'We have a feeling that even though they're saying it's consensual in a sense, we have a feeling it's not going to be treated as such, and it's not going to get the proper disclosures and the proper sense,' Payne said.
The Department of Health and Human Services denies an autism registry is being created, despite what its director announced days prior. An official did not clarify to CBS News if the director misspoke, or if the plan was reversed. The Department did say the data platform it will use to study causes of autism will use existing datasets. Payne said no matter what is used, it cannot have a 'quick fix' approach.
'It's a very complex developmental disorder,' Payne said. 'It's a wide spectrum. You can't just say that we're going to find effective treatments in a certain time, this has taken years to even understand.'
The National Institute of Health told CBS News it still plans to explore partnerships with other federal agencies including the Centers for Medicare and Medicaid Services. An official said the dataset will maintain the highest standard of security and patient privacy — similar to the agency's cancer database. Saying, 'these efforts are not about tracking individuals.'
With what Payne calls back and forth at the national level, Payne is writing to United States Secretary of Health and Human Services Robert F. Kennedy Jr. himself with a cease and desist.
'This is an issue that needs to be addressed, essentially,' Payne said. 'They say it's going to be fairly transparent and all that. But we haven't seen that yet from their face.'
The National Institue of Health Director said the anticipated grant funding the autism research should be awarded by September.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
5 hours ago
- The Hill
Warren questions HHS general counsel nominee about vaccines, abortion
Senator Elizabeth Warren (D-Mass) on Thursday will press West Virginia state Senator Mike Stuart (R) about how his beliefs on topics like vaccines and abortion will impact how he potentially serves as general counsel of the Department of Health and Human Services. Stuart supported a state bill that would have allowed for exemptions in West Virginia's school vaccination policy. He has also referred to himself as 'unapologetically pro-life' and has been proud to be endorsed by West Virginians for Life in a post on X. President Donald Trump tapped Stuart to serve as the top lawyer for the agency in February, and the Senate Finance Committee is scheduled to consider his nomination Thursday at 10 a.m. If confirmed, Stuart will be responsible for giving legal advice to Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and Deputy Secretary Jim O'Neil, who have already instituted numerous changes to the agency, like sweeping layoffs and firings. 'Your interpretation of the law plays a critical role in ensuring that HHS is achieving its goal of 'protecting the health of all Americans,'' Warren wrote in a letter to Stuart shared first with The Hill. 'But given your ideological views, zealous for restrictions on abortion, and record of anti-vaccine skepticism, I am concerned that, rather than faithfully following the law, you will greenlight Trump Administration policies that will endanger public health, strip Americans of their abortion rights, and cause millions of Americans to lose their health insurance.' In the letter, Warren asks Stuart to come to the hearing with written answers to more than 70 questions on vaccines, abortion access, staffing cuts, Medicaid and the implementation of the 'One Big Beautiful Bill Act.' 'HHS carries an enormous responsibility as its services and programming touch millions of American lives every day,' Warren's letter reads. 'The chief legal adviser to the Secretary of HHS must be able to, without bias, effectively advise the Secretary to ensure that all actions by HHS are in accordance with the law.'
Los Angeles Times
a day ago
- Los Angeles Times
FDA vaccine chief leaving agency after less than 3 months
WASHINGTON — The Food and Drug Administration's polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of biotech executives, patient groups and conservative allies of President Trump. Dr. Vinay Prasad 'did not want to be a distraction' and was stepping down from his role as the FDA's top vaccine regulator 'to spend more time with his family,' a spokesperson for the Department of Health and Human Services said in a statement late Tuesday. Two people familiar with the situation told the Associated Press that Prasad was ousted following several recent controversies. The people spoke on condition of anonymity to discuss internal personnel matters. Prasad did not immediately respond to requests for comment Wednesday morning. Prasad joined the FDA in May after years as an academic researcher at UC San Francisco, where he frequently criticized the FDA's approach to drug approvals and COVID-19 vaccines. His contrarian approach appeared to match FDA Commissioner Marty Makary, who repeatedly praised Prasad's work and intellect. But in recent weeks, Prasad became a target of right-wing activists, including Laura Loomer, who flagged Prasad's past statements criticizing Trump and praising liberal independent Sen. Bernie Sanders of Vermont. 'How did this Trump-hating Bernie Bro get into the Trump admin???' Loomer posted on X last week. Trump previously fired several national security officials a day after Loomer raised concerns about their loyalty. Prasad also attracted scrutiny for his handling of a recent safety issue surrounding the only approved gene therapy for Duchenne's muscular dystrophy. Under his direction, shipments of the therapy were briefly halted after a series of patient deaths, then resumed late Monday following vocal pushback from families of boys with the fatal muscle-wasting disorder. Prasad has long been skeptical of the therapy and other muscular dystrophy drugs sold by the drugmaker, Sarepta Therapeutics. As an academic, Prasad gained prominence by attacking the FDA for being too lenient in its standards for approving cancer drugs and other new therapies. That approach is at odds with Trump's Republican supporters, who generally favor speedier approvals and unfettered access to experimental treatments. During Trump's first term, he signed the 'Right to Try' law, a largely symbolic piece of legislation that won popular support from conservatives seeking to give dying patients expanded access to unproven drugs. Prasad's decision to pause Sarepta's therapy was criticized last week by a columnist and the editorial board of the Wall Street Journal. Separately, Prasad's division issued rejection letters this month to three small biotech firms seeking approval for new gene therapies. Those therapies have been vigorously embraced many of the antiabortion groups in Trump's base for their potential to address intractable diseases that sometimes lead parents to terminate pregnancies. Prasad's predecessor in the role, Dr. Peter Marks, oversaw a dramatic rise in approvals for new gene therapies, which aim to treat or prevent disease by replacing or modifying a portion of patients' genetic code. Prasad has been an outspoken critic of Marks' leadership at the FDA, which included overseeing the approval of the first COVID vaccines and therapies. Perrone writes for the Associated Press. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
The Hill
a day ago
- The Hill
New bill outlines federal grants for uterine fibrosis in bipartisan health push
Sens. Angela Alsobrooks (D-Md.) and Cynthia Lummis (R-Wyo.) will introduce a bill to award federal grants to study uterine fibroids as one of several competing bipartisan measures to support study of the noncancerous growths common in women of childbearing age. The bill would establish a new grant program of unspecified amount and duration to support research on early detection of and intervention for uterine fibroids, including screening procedures. Alsobrooks is also a cosponsor on a separate bipartisan measure, introduced by Sen. Cory Booker (D-N.J.), that would carve out $30 million over four years to study uterine fibroids, although not necessarily through a direct grant program. A spokesperson for the Maryland senator's office said the two 'approaches need to work in tandem — supporting direct research dollars, while also empowering the [Health and Human Services] Secretary to support innovative programs across the country that can reach patients where they are in community.' Eligible topics under the grant program would include disparities in pain control in surgery for uterine fibroids, as well as conditions like Asherman's Syndrome, where scar tissue builds up inside the uterus. Alsbrooks and Lummis's bill would also support programs to raise awareness for uterine fibroids. 'For too long, uterine fibroids have plagued women. We need to invest in research, raise public awareness, and develop programs for early treatment,' Alsobrooks said in a statement. 'I am proud to reach across the aisle and partner with Senator Alsobrooks to ensure women in Wyoming and across the country suffering from uterine fibroids no longer suffer in silence,' Lummis said in a statement. 'Our bipartisan legislation will expand access to screenings and intervention, providing hope to the millions of women who endure this painful condition.' The push to study the health condition, estimated to affect 40 percent to 80 percent of women, comes after the Trump administration has pushed to cancel research grants related to 'diversity, equity and inclusion,' health equity and other topics it deemed to be wasteful. The Department of Health and Human Services has pulled at least two grants this year directly studying uterine fibroids, including a $1.5 million study at the University of Texas and a doctoral student's fellowship at Columbia University. The bill, officially called the Uterine Fibroid Intervention and Gynecological Health Treatment (U-FIGHT) Act, also has a companion in the House introduced by Rep. Shontel Brown (D-Ohio) as part of a larger legislation package on women's health. Brown's group of bills includes a law to study the relationship between hair straighteners and uterine cancer. Lummis is the first Republican senator to support the U-FIGHT Act. The bill has also won the support of actress Lupita Nyong'o, who was diagnosed with uterine fibroids and had surgery to remove them.
